ReviewFrontiers in microbiology2026
Liposome drug delivery strategies: state-of-the-art for combating bacterial biofilms.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial biofilms pose a significant challenge in clinical settings due to their inherent resistance to conventional antibiotics and host immune responses. This review comprehensively discusses the application of liposomal drug delivery systems as a cutting-edge strategy to combat biofilm-associated infections. It begins by outlining the biological characteristics of biofilms, including their formation process and the protective extracellular polymeric substance (EPS) matrix. The manuscript then focuses on the advantages of liposomes, such as their nanoscale size effect, modifiable surface properties, and sustained-release capabilities, which enhance penetration through the EPS and improve drug accumulation at infection sites. Furthermore, it details species-specific strategies against pathogens like
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.